
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
Key takeaways Orphan drug designation for quemliclustat highlights regulatory momentum and unmet need in pancreatic cancer treatment development. PRISM-1 Phase III trial design reflects gold-standard methodologies (randomized, double-blind, placebo- …